Pancreatic cancer data focus: Social media conversations center on Immuneering's planned presentation at an upcoming AACR conference. The spotlight is on Atebimetinib and its reported ability to reduce tumor volume while preserving body mass. Observers note the potential for extended survival in pancreatic cancer models.
Summit participation noted: Recent activity highlights the company's attendance at the RAS-Targeted Drug Development Summit in Boston. Participants share details on pipeline progress and dual-mechanism approaches. The discussion underscores ongoing research efforts in targeted therapies.
Market positioning comments: Some posts reference IMRX within broader lists of biotech names with elevated short interest. This has prompted remarks on possible volatility tied to clinical catalysts. Sentiment remains focused on the implications of forthcoming data releases.
Note: This discussion summary was generated from an AI condensation of post data.
Immuneering Insider Trading Activity
Immuneering insiders have traded $IMRX stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $IMRX stock by insiders over the last 6 months:
- BRETT MATTHEW HALL (CHIEF SCIENTIFIC OFFICER) purchased 6,035 shares for an estimated $25,045
- BENJAMIN J. ZESKIND (PRESIDENT AND CEO) purchased 2,400 shares for an estimated $10,948
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Immuneering Hedge Fund Activity
We have seen 70 institutional investors add shares of Immuneering stock to their portfolio, and 55 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 2,866,762 shares (+190.2%) to their portfolio in Q2 2026, for an estimated $14,305,142
- EMPERY ASSET MANAGEMENT, LP removed 2,674,950 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $13,348,000
- MARSHALL WACE, LLP removed 1,264,688 shares (-63.3%) from their portfolio in Q2 2026, for an estimated $6,310,793
- MILLENNIUM MANAGEMENT LLC removed 772,310 shares (-70.0%) from their portfolio in Q2 2026, for an estimated $3,853,826
- STATE STREET CORP added 733,475 shares (+273.2%) to their portfolio in Q2 2026, for an estimated $3,660,040
- GEODE CAPITAL MANAGEMENT, LLC added 732,806 shares (+114.9%) to their portfolio in Q2 2026, for an estimated $3,656,701
- BLUE OWL CAPITAL HOLDINGS LP removed 665,000 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $3,504,549
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Immuneering Analyst Ratings
Wall Street analysts have issued reports on $IMRX in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Cantor Fitzgerald issued a "Overweight" rating on 07/08/2026
- Chardan Capital issued a "Buy" rating on 05/19/2026
To track analyst ratings and price targets for Immuneering, check out Quiver Quantitative's $IMRX forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
